Rheumatoid Arthritis

Jeffrey Curtis, MD, discusses how the Vectra test can be a useful tool for rheumatologists at ACR 2019.

Daniel Clauw, MD, of the University of Michigan, discusses the impact public perception has had on pain management practices for patients with rheumatic diseases and chronic pain.

Using the largest SLE birth cohort ever established, investigators determined children exposed to non-TNF inhibitors in utero were at a low risk of serious infection.

A 19-year analysis presented at ACR 2019 has found opioid use disorder hospitalizations among some rheumatic diseases have increased more than 30-fold since 1998.

A new study presented at ACR 2019 is debunking the notion that use of ultrasound to guide treatment in early rheumatoid arthritis provides added benefit over conventional treatment strategies.

A new study presented at ACR 2019 has found spending on bDMARDs nearly doubled between 2012 and 2016, with post-market drug price changes driving most of the increase.

A study presented at CCR West found that tocilizumab displayed better biologic persistence compared with other biologics in patients with rheumatoid arthritis who previously received 1 or more other biologics.

Sheetal Desai, MD, AWARE investigator and assistant clinical professor of medicine at UC Irvine, discusses full 52-week results of study comparing 2 popular rheumatoid arthritis patients and what the observed safety profile means from a patient-centered perspective.

Aaron Broadwell, MD, rheumatologist and AWARE investigator, discusses his interpretation of the full 52-week results of the trial, which examined golimumab and infliximab in patients with rheumatoid arthritis in a real-world setting.

A post hoc analysis presented at CCR West found sarilumab outperformed adalimumab and placebo in HbA1c improvement in rheumatoid arthritis patients with diabetes.

A study examining a gene expression classifier from Scipher Medicine called PrismRA found the system could be used to identify at least half of the non-responders with at least 90% accuracy.

Theresa Lawrence Ford, MD, CEO and medical director of North Georgia Rheumatology Group and board member of the Association of Women in Rheumatology, gives her opinion on the current state of burnout among rheumatologists.

Sheetal Desai, MD, a rheumatologist and investigator of the ongoing AWARE trial, discusses her clinical takeaways from the 52-week results and the importance of real-world evidence.

AWARE Trial investigator Aaron Broadwell, MD, discusses what new data was presented during CCR West and how it differed from a previously presented interim analysis.

A new study from CCR West compared the JAK inhibitor therapy to competitors across a clinical trial program involving 5 pivotal phase 3 studies.

Maria Greenwald, MD, rheumatologist, discusses what she sees as a glaring issue in medicine—the lack of knowledge among many physicians as to how much treatments will cost and how to mitigate the impact of those costs.

While conferences and annual meetings are often the place clinicians are exposed to new data, there are often niche areas where they seek further guidance or information. Janet Pope, MD, discusses where she would like to see more research dedicated.

Janet Pope, MD, professor of medicine at the University of Toronto, discusses whether she believes clinicians will ever transition away from DMARDs and biologics due to the high cost and what the alternatives are for those patients.

Elena Myasoedova, MD, of the Mayo Clinic, discusses the results of a study examining the incidence rates of cardiovascular disease in patients with rheumatoid arthritis across 3 decades.

Rania Al Asmar, MBBS, discusses a study she led and authored that examined prevalence and characteristics of patients with rheumatoid arthritis who later developed coronary artery disease.

Jack Stacy, MSIV, of University of North Dakota, discusses a study he co-authored and presented at CCR West examining the use of low-dose prednisone to induce remission in patients with rheumatoid arthritis.

Janet Pope, MD, a professor at the University of Toronto and CCR Faculty member, discusses what her biggest takeaways and highlights from the first day of CCR West in San Diego.

A cohort assessment of patients treated in a rural academic-based clinic finds just 10% of patients were vaccinated for the disease their RA therapies put them at more risk for.

In a small pilot study, investigators find medication non-adherence leads to more hospitalization of SLE patients.

A new study shows adherence to current ACR guidelines for therapy results in improved disease activity scores.

In new data presented at CCR West, investigators link smoking and ethnicity with organ damage of SLE patients.

The JAK inhibitor from AbbVie has shown significant benefit for RA patients over 2 weeks of treatment.

The JAK inhibitor could receive consideration as a rheumatoid arthritis therapy in both Europe and the US in the following year.

The FDA suggests only limited use of tofacitinib to treat rheumatoid arthritis, ulcerative colitis, or psoriatic arthritis.

Investigators found positive results when examining the safety and efficacy of filgotinib in the FINCH 2 phase 3 clinical trial.